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Platelets have become a popular model for the 
monoaminergic neurons and especially for studies of 
serotonin uptake and metabolism [1,2]. Considering 
that human platelets can be obtained very easily, 
studies were directed towards comparing storage, 
metabalism and uptake of serotonin in various 
~eurolo~c~ and mental illnesses [3,4]. Differences 
have been reported in serotonin levels and MAO 
activity between schizophrenics and healthy people 
[S $1. This led to the hypothesis that the pharmaco- 
dynamics of blood platelet serotonin is abnormal 
in certain conditions characterized by disturbed brain 
functions. If platelet serotonin is a reflection of mal- 
function ofindolalkylamine metabolism, such platelet 
abnormalities may reflect changes that have occurred 
in scrotonin-containing neurons in the central nervous 
system. 
We have shown [7] that the active uptake of sero- 
tonin in schizophrenic patients in acute state is much 
lower (35%) than that of control group. We would 
like to report here b~ochemic~ and ph~rmacolo~c~ 
properties related to this si~i~can~y lower uptake. 
These b~ochemic~ parameters may give some indica- 
tion of the serotonin carrier condition in the platelet 
membrane, 
2. Methods 
Blood was drawn from patients or control vofun- 
teers with ACD (NIH solution A) as ant~c#ag~ant. 
Biood (8.5 ml) was collected into a plastic tube con- 
taining 1.5 ml anticoagulant ~trisodium citrate 
134 
dihydrate (2.2 g), citric acid monol~ydrate (a,& g), 
and glucose r~~o~lohydrate (2.5 g>; diluted to 100 ml 
with double~distilled water). After 3 consecutive 
centrifugations at 4’C and removal of the red blood 
cells, the platelet rich plasma (PRP) was obtained. 
PRP (475 ~1) were preincubated at 37°C for S nun in 
Eppendorf plastic tubes and the uptake was initiated 
by the addition of25 ~1 t3HJserotonin sohttion 
(2X 10-“M).Tl te m serotonin concentratior~ was f al 
1 X 1K7 M. Uptake was studied over a period of 
S min at 37°C then the tubes were immediately 
cooled to 2% and centrifuged in ffeckman Microfuge 
for 2 min. The s~per~~atant was removed and the 
platelet pellet was washed 3 times with saline con- 
taining 1 mM EDTA and counted, using scintillation 
mixture prepared from: 2,Sdiphenyloxazol (8 g); 
1,4-di-2-(4”methyl-S-phynyloxazolyl)-benzene 
(200 mg); toluene (1320 ml); Triton X-100 (660 ml). 
Inhibition studies were carried out by preincubation 
of the PRP with the inhibitor at the appropriate con- 
centration for 5 min and then the serotonin uptake 
was initiated as described above. Platelets were 
counted after fixation of 0.1 ml PRF with 2 ml solu- 
tion: form~de~yde (0.25%); acetone (2.5%); saline 
{2.5%). 
3. Results 
Figure 1 shows a time course of serotonin uptake 
at 1 X 10V7 M. Xt is clear that the uptake is linear 
with time for -6 min then levels off. Accordin~y all 
our studies were done over an incubation period of 
5 min. The effect of ~t~schizo~~ren~c drugs on the 
uptake in vitro w3s studied using the same drugs 
Volume 101, number 1 FEBS LETTERS May 1979 
lncubotmn +me (mini [Log concentration of Drug]xlO* (Ml 
Fig.1. Time course of serotonin uptake by human platelets. 
Serotonin, 1 X IO-’ M. 
which were used by the patients in the study. Results 
shown in fig.2,3 indicate that these drugs have no 
effect on the active uptake of serotonin at 10-6-10-7 M 
(where the antidepressants imipramine and ami- 
tryptaline show 80-99s inhibition). Our most 
interesting result is shown in fig.4, where the active 
uptake was studied as a function of concentration. 
Patients exhibit a saturable active transport with Km 
1.8 X 10W6 M and V,, 250 pmol serotonin/~O’ 
platelets/5 min. Control (healthy human volunteers) 
also show a saturable process with Km 1.8 X 1 0m6 M 
and Vmax 350 pm01 serotonin/lO* platelets/S min. 
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Fig.2. Human platelet serotonin uptake inhibition by chlor- 
promatine (0) and valium (o) measured over 5 min incuba- 
tion with serotonin at 1 X LO-’ M. 
Fig.3. Human platelet serotonin uptake ~hibition by l&dot 
to), Neuleptyl (o), and Melleryl (A), measured over 5 min 
incubation with serotonin at 1 X lo-’ M. 
4. Discussion 
The uptake of serotonin by human blood platelets 
is believed to be mediated by a carrier located in the 
cell membrane [S,9]. The affinity of the substrate 
(serotonin) towards the carrier is given by the Km 
value while the Ymax of the process is proportional to 
the number of carriers or receptors present. Our 
results indicate that the maximum velocity of sero- 
tonin transport into 1 cell is 7000 molecules/s in the 
control group and only 5000 molecules/s in the 
patients. It was reported [lo] that human platelets 
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Fig.4. Uptake to serotonin by blood platelets of controls (0) 
and patients (o) as a function of serotonin concentration over 
5 mm incubation. Values are average of duplicates of 4 experi- 
ments. Insert: Lineweaver-Burk analysis. 
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contain 2 binding sites/serotonin. The high affinity 
site is probably associated with shape change while 
the low affinity site (with a capacity of 4000 sites/ 
cell) is associated with uptake. If we assume that each 
binding site corresponds to a carrier this means that 
each carrier can transport 1 molecule of serotonin in 
0.57 s. The fact that the V,, in patients was much 
lower than that of controls means that the number 
of carriers in patients is lower than in the healthy 
control group. However, the identical Km values in 
the two groups indicate that each carrier shows the 
same affinity towards the serotonin molecule and 
either carrier (in the schizophrenic patients or the 
controls) will transport 1 molecule of serotonin into 
the cell in 0.57 s. 
This study gives a molecular and biochemical 
dimension to the search for the etiology of schizo- 
phrenia. The assay of serotonin transport was con- 
ducted in a way eliminating metabolic processes and 
diffusion (by a short incubation time). Thus, the 
process studied was a membrane phenomenon not 
affected by the drug taken by patients but dependent 
rather on the nature and properties of the serotonin 
carrier. The nature of the lower number of carriers in 
patients is not yet understood, nor its significance for 
a probable difference in the brain. Further studies in 
this direction are now in progress in our laboratory. 
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